Adlon Therapeutics, a subsidiary of Purdue Pharma
Adlon Therapeutics’s Adhansia XR is a central nervous system stimulant that is used for the treatment of attention deficit hyperactivity disorder (ADHD) in people ages 6 and older.
Common adverse reactions associated with taking Adhansia XR in adults are insomnia, dry mouth and decreased appetite. Common adverse reactions in pediatric patients include decreased appetite, insomnia and weight decreased.
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs